Regarding specifically to the emergence of TDLs following alemtuzumab treatment in MS, the only reported case associates the TDLs with an increase in B-cells and a decrease in CD4+ and CD8+ T-cells in peripheral blood (6). The gene discussed is CD4; the disease is myeloid sarcoma.